UNSPSC 51451605: Oxibendazole

This classification denotes an antihelminthic agent with the molecular formula C12H15N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 022N12KJ0X, chemically known as 2-benzimidazolecarbamic acid, 5-propoxy-, methyl ester but generally known as oxibendazole, which bears US NIH Compound Identifier 4622. European Medicines Agency schedules Oxibendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09521MIG.

UNSPSC 51451605 Oxibendazole is a Commodity code that in practice does not map to the recent state and local opportunities posted under it. The code nominally represents a specific antiparasitic veterinary pharmaceutical, but the recent solicitations tagged to this code cover naloxone (an opioid antagonist), medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription program capabilities. None of these are oxibendazole or closely related to veterinary antiparasitic products. The opportunities reflect health and safety procurement by county health departments, municipal fire departments, state health and human services agencies, and multistate cooperative purchasing alliances — entities that typically procure finished medical products, emergency supplies, and pharmacy benefit services rather than bulk active pharmaceutical ingredients or veterinary therapeutics.

State and local procurement activity under this code shows minimal relevant recent volume. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (a date discrepancy in the source). The City of Tampa posted IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department, estimated at $700,000 and designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The mismatch between the code's defined scope and actual procurement activity suggests either a tagging error by the issuing jurisdictions or that this code is not actively used for state and local procurement in its intended sense.